You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.



Kedrion Biopharma supports the launch of "Nature Italy"

The Company reaffirms and strengthens its commitment to research and innovation

read more 


Kedrion announces the appointment of a new CEO

Val Romberg from the USA, one of the most esteemed managers in the industry

read more 


Kedrion supports the 2020 European Hemophilia Consortium Conference

The company renews its commitment alongside the EHC, which continues to support the PARTNERS project

read more 
  1. CORPORATE - 01-09-2020

    KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH

    Further step towards an even stronger focus on patients in Europe

    read more 
  2. PLASMA & BIOTHERAPIES - 21-08-2020

    First and Only US Pediatric human rabies Immune globulin Trial

    Kedrion-Kamada Announce Study Met Its Primary Objective

    read more 
  3. CORPORATE - 28-07-2020

    Kedrion’s Mother and Child Health campaign for Asia and MEA announced

    Details were unveiled during our first televised Regional Distributor Meeting on July 14th-15th

    read more 


For more information please contact: